Neuraxpharm

Neuraxpharm, a pharmaceutical preparation manufacturer, reported total emissions of approximately 126,799,710 kg CO2e in 2025. This includes about 2,162,030 kg CO2e from Scope 1 emissions, 1,790,610 kg CO2e from Scope 2 emissions, and 122,847,070 kg CO2e from Scope 3 emissions.

In 2024, Neuraxpharm's total emissions were approximately 119,136,260 kg CO2e, comprising around 2,052,450 kg CO2e in Scope 1, 1,966,500 kg CO2e in Scope 2, and 115,117,310 kg CO2e in Scope 3. The company's total emissions for 2023 were approximately 117,214,390 kg CO2e, with Scope 1 emissions at about 1,655,640 kg CO2e, Scope 2 at 1,757,390 kg CO2e, and Scope 3 at 113,801,360 kg CO2e.

For 2022, Neuraxpharm reported total emissions of approximately 3,526,000 kg CO2e, with Scope 1 emissions of about 2,064,000 kg CO2e and Scope 2 emissions of approximately 1,462,000 kg CO2e. Scope 3 data was not provided for this year. In 2021, the company's Scope 1 emissions were approximately 389,000 kg CO2e and Scope 2 emissions were about 749,000 kg CO2e. For 2020, Scope 1 emissions were around 658,000 kg CO2e and Scope 2 emissions were approximately 2,038,000 kg CO2e. Scope 3 data was not provided for 2021 or 2020.

Neuraxpharm has not disclosed any specific emissions reduction targets or commitments, such as Science Based Targets (SBTi).